AI Verdict
PAHC has stronger fundamentals based on our AI analysis.
PALI vs PAHC Fundamental Comparison
| Metric | PALI | PAHC |
|---|---|---|
| Revenue | $0.0 | $737.8M |
| Net Income | $-16.8M | $54.0M |
| Net Margin | N/A | 7.3% |
| ROE | -13.0% | 16.2% |
| ROA | -12.5% | 3.8% |
| Current Ratio | 28.95x | 3.05x |
| Debt/Equity | 0.00x | 1.88x |
| EPS | $-0.30 | $1.32 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PALI vs PAHC: Frequently Asked Questions
Is PALI or PAHC a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PAHC has stronger fundamentals. PALI is rated SELL (68% confidence) while PAHC is rated HOLD (62% confidence). This is not investment advice.
How does PALI compare to PAHC fundamentally?
PALISADE BIO, INC. has ROE of -13.0% vs PHIBRO ANIMAL HEALTH CORP's 16.2%. Net margins are N/A vs 7.3% respectively.
Which stock pays higher dividends, PALI or PAHC?
PALI has a dividend yield of N/A or no dividend while PAHC has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PALI or PAHC for long term?
For long-term investing, consider that PALI has SELL rating with 68% confidence, while PAHC has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PALI vs PAHC?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PALI vs PAHC, the AI consensus favors PAHC based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.